Aventis Pharma S.a.

Sanofi

Aventis Pharma Limited

Pierre Mourier

Christian Viskov

Luc Grondard

Elisabeth Perrin

Vesna Biberovic

Jean-Marie Stutzmann

Volker Laux

Florence Wahl

Gerald Perret

Florence Chez M Karoby Wahl

The invention relates to sulphated polysaccharides which have the general structure of the constituent polysaccharides of heparin and which have a molecular weight of less than 8000 Daltons, comprising two antithrombin III-binding hexasaccharide sequences corresponding to formula (I) in which: R1 represents an OH group when the hexasaccharide of formula (I) is located at the reducing end of the polysaccharide, or else R1 represents a bond with another saccharide unit of said polysaccharide; R2 represents a hydrogen atom when the hexasaccharide of formula (I) is located at the non-reducing end of the polysaccharide, in which case the bond between carbon atoms 4 and 5 of the first saccharide unit of said hexasaccharide is a double bond, or else R2 represents a bond with another saccharide unit of said polysaccharide, in which case the bond between carbon atoms 4 and 5 of the first saccharide unit is a single bond. Preparation thereof, use thereof as antithrombotic medicaments, and also use thereof in a method for analyzing a sample of a heparin derivative. 

Polysaccharides comprising two antithrombin III-binding sites, preparation thereof and use thereof as antithrombotic medicaments

The present invention is directed to an affinity chromatography column comprising the antithrombin III (ATIII) protein bound to a solid support, characterized in that:

Method for affinity chromatography of antithrombin III

The instant invention relates to decasaccharides of formula (I): 

Acylated decasaccharides and their use as antithrombotic agents

The instant invention relates to the heptasaccharide of formula (I): 

Sulfated heptasaccharide and its use as an antithrombotic agent

The instant invention relates to the decasaccharide of formula (I), wherein Ac represents an acetyl group: in its acid form or in the form of any one of its pharmaceutically acceptable salts, and to its process of preparation. The oligosaccharide of formula (I) is useful as an antithrombotic agent.

Acylated 1,6-anhydro decasaccharide and its use as an antithrombotic agent

The present invention relates to mixtures of polysaccharides derived from heparin having a mean molecular weight of 1500 to 3000 Daltons and an anti-Xa/anti-IIa ratio greater than 30, their method of preparation and pharmaceutical compositions containing them.

Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them

Mixtures of sulfated oligosaccharides

Oligosaccharide mixtures comprising anti-Xa activities of from 190 IU/mg to 450 IU/mg and anti-IIa activities of less than 0.2 IU/mg; and having constituent oligosaccharides with an average molecular weight of from 1800 to 2400 Daltons, constituent oligosaccharides comprise from 2 to 16 saccharide units, a 4,5-unsaturated uronic acid 2-O-sulfate unit at one end, and comprising at least one &#x394;IIa-II-Is hexasaccharide sequence are described. Processes for preparing the oligosaccharide mixtures, pharmaceutical compositions and articles of manufacture comprising the oligosaccharide mixtures are described. Methods of treatment and prevention comprising administering the oligosaccharide mixtures are described.

Oligosaccharide mixtures derived from heparin, preparation thereof and pharmaceutical compositions containing them

The invention provides methods for analyzing heparins, low-molecular-weight heparins, ultralow-molecular-weight heparins, and oligosaccharides by high performance liquid chromatography a stationary phase dynamically coated with a quaternary ammonium salt. The methods of the invention may be used to analyze samples without pre-treatment or to analyze samples that have been partially or exhaustively depolymerised and, optionally, reduced. Specific saccharides can be detected.

Method for determining specific groups constituting heparins or low molecular weight heparins

The present invention relates to a method for analyzing oligosaccharides constituting the heparins of low molecular weight and the heparins of very low molecular weight from blood plasma.

Growing community of inventors

Charenton le Pont, France

Pierre Mourier